Shots:

• Quebec will follow a similar approach to policies introduced in British Columbia- Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar. This will contribute to annual savings that can be reinvested in healthcare and innovative new drugs
• The transition will take place under the supervision of the attending physicians & patients will continue receiving safe & effective treatment
• Sandoz Canada is committed to supporting patients- their HCPs- and the Quebec government throughout the transition period with quality biosimilar medicines- medical teams- physician- and pharmacist advocacy teams- as well as with patient support programs

Ref: Sandoz| Image: Sandoz